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Background: The actions of caffeine as an antagonist of adenosine receptors have
been extensively studied, and there is no doubt that both daily and sporadic dietary
consumption of caffeine has substantial biological effects on the nervous system.
Caffeine influences headaches, the migraine syndrome in particular, but how is unclear.
Materials and Methods: This is a narrative review based on selected articles from
an extensive literature search. The aim of this study is to elucidate and discuss how
caffeine may affect the migraine syndrome and discuss the potential pathophysiological
pathways involved.
Results: Whether caffeine has any significant analgesic and/or prophylactic effect
in migraine remains elusive. Neither is it clear whether caffeine withdrawal is an
important trigger for migraine. However, withdrawal after chronic exposure of caffeine
may cause migraine-like headache and a syndrome similar to that experienced in
the prodromal phase of migraine. Sensory hypersensitivity however, does not seem
to be a part of the caffeine withdrawal syndrome. Whether it is among migraineurs
is unknown. From a modern viewpoint, the traditional vascular explanation of the
withdrawal headache is too simplistic and partly not conceivable. Peripheral mechanisms
can hardly explain prodromal symptoms and non-headache withdrawal symptoms.
Several lines of evidence point at the hypothalamus as a locus where pivotal actions
take place.
Conclusion: In general, chronic consumption of caffeine seems to increase the burden
of migraine, but a protective effect as an acute treatment or in severely affected patients
cannot be excluded. Future clinical trials should explore the relationship between caffeine
withdrawal and migraine, and investigate the effects of long-term elimination.
Keywords: headache, caffeine, adenosine, dopaminergic, histaminergic, circadian, yawning, withdrawal
“I am not acquainted with any agents which equal these substances (coffee and tea, aa), in the power of
removing headache without leaving inconvenient results. And as their physiological action is so purely
cerebral, restoring the intellectual faculties, and ministering to the sensations of well-being, as well as
lessening any sad emotions, we have here an adequate presumption, were any required, that this headache
is seated in the nerves, which are immediately related with the molecular action of the brain.”
John Addington Symonds, the Goulstonian lecture for 1858 (1)
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INTRODUCTION
It is well-know that caffeine can stimulate wakefulness, increase
concentration and decrease the sensation of fatigue (2), but how
does it affect one of the most common human agonies (3),
headaches? Caffeine is commonly used as analgesic adjuvant
for the acute treatment of pain. However, despite the flattering
description of the efficacy above, the general analgesic effect of
caffeine seems at best modest (4). Besides, chronic consumption
of it may have a flip side, withdrawal may cause caffeine
withdrawal (5, 6), a syndrome including symptoms such as
drowsiness, headache, mood-changes, difficulty focusing, nausea
and muscle pain/stiffness (Box 1). Even small amounts of
caffeine have been shown to suppress this (5). Headache
can occur independently of the other symptoms (7), and
Caffeine-withdrawal headache (Box 2), properly described in
the 1940s (8, 9), is recognized as an own diagnostic entity
by the International Classification of Headache Disorders
(ICHD-3) (10). Results from both experimental and clinical
studies indicate a high rate of caffeine withdrawal in the
modern society, that may even be underestimated (5). The
real world extent and clinical (physiological and psychological)
importance are not well-known (11). The dual effects of
caffeine in headaches, relieving on one side and triggering on
the other side, make caffeine a very interesting substance in
headache pathophysiology research. Still, the prevailing theory
of the withdrawal headache is basically a rebound vasodilation
due to caffeine’s vasoconstrictive effect (12), at large a too
simplistic theory that is not in conformity with modern views
of headache pathophysiology (13). The caffeine withdrawal
syndrome, which includes symptoms suggestive of the prodromal
phase of migraine, is hardly of peripheral origin. Based on the
current established knowledge on migraine pathophysiology,
this narrative review aims to explore how caffeine, which has
profound biological effect as an adenosine receptor antagonist
(14), may influence pathways involved in headaches, with a
particular focus in migraine.
BOX 1 | Diagnostic criteria for Caffeine-withdrawal according to the
DSM-5.
A. Prolonged daily use of caffeine.
B. Abrupt cessation of caffeine use, or reduction in the amount of caffeine
used, followed within 24 h by 3 or more of the following symptoms:
a) Headache.
b) Marked fatigue or drowsiness.
c) Dysphoric or depressed mood, or irritability.
d) Difficulty concentrating.
e) Symptoms of nausea, vomiting, or muscle pain/stiffness.
C. Clinically significant distress or impairment in social, occupational, or other
important areas of functioning.
D. Not due to the direct physiological effects of a general medical condition
and are not better accounted for by another mental disorder.
BOX 2 | Diagnostic criteria for Caffeine-withdrawal headache according to
the ICHD-3.
A. Headache fulfilling criterion C.
B. Caffeine consumption of >200 mg/d for > 2 weeks, which has been
interrupted or delayed.
C. Evidence of causation demonstrated by both of the following:
1. Headache has developed within 24 h after last caffeine intake
2. Either or both of the following:
a) Headache is relieved within 1 h by intake of caffeine 100mg.
b) Headache has resolved within 7 days after caffeine withdrawal.
D. Not better accounted for by another ICHD-3 diagnosis.
MATERIALS AND METHODS
The article is based on unsystematic searches in PubMed
with terms like “caffeine and headache,” “caffeine withdrawal,”
“adenosine and headache,” with more, and on own knowledge of
older and recent literature on migraine. A discretionary selection
of publications was made.
RESULTS AND DISCUSSION
Caffeine and Adenosine
Caffeine is a major constituent of coffee and tea, but also naturally
occur in guarana, cola nuts, cocoa, and several other plants (2).
Soft drinks, energy drinks, and dietary supplements are also
important sources, in particular among the younger population
(15). The typical level in an ordinary cup of coffee varies between
50 and 100mg (2). After oral ingestion, caffeine is rapidly and
completely absorbed (99%), with peak plasma concentration
reached usually within an hour (16, 17). Caffeine passes through
all biological membranes, including the blood-brain barrier, and
is distributed in all body fluids (18). It is metabolized by the
cytochrome P450 system, the isoenzyme CYP1A2 responsible for
90% of caffeine clearance, and in adults it has a typical half-life
of 5 h (19). Numerous factors, including a broad and variable
genetic basis (20, 21), modify caffeine clearance.
The actions of caffeine in doses relevant to human
consumption (50 to several 100 milligrams) are through
antagonism of G protein-coupled purinergic (P1) receptors,
more specifically the adenosine receptors (ARs), preferentially
the A1R and A2AR (18, 22, 23). The human genes encoding for
these two receptors are ADORA1 and ADORA2, respectively.
Single nucleotide polymorphisms (SNPs) in ADORA2 appear
to play a role in an individual’s subjective response to
caffeine (24–26).
Adenosine is found in every cell in the form of adenosine
5′-diphosphate (ADP) or adenosine 5′-triphosphate (ATP). It is
continuously formed by breakdown of ATP and the physiological
effects of adenosine are directly related to the metabolic activity
(27). It modulates the activity of numerous cells, including mast
cells, smooth muscle cells, platelets, and neurons (28). In the
nervous system, adenosine appears to play an important role in
Frontiers in Neurology | www.frontiersin.org 2 December 2019 | Volume 10 | Article 1275
Alstadhaug and Andreou Caffeine and Primary (Migraine) Headaches
modulating brain neurotransmitter release, locomotion, reward,
sleep/wakefulness, cognition, and analgesia (14). Adenosine is
neither stored nor released as a classical neurotransmitter, but
may exert marked effects on neuronal excitability through G
protein-coupled adenosine receptors (AR) A1, A2A, A2B, and
A3 in both the peripheral and the central nervous system. The
A1R is virtually found everywhere in the brain. In general
it mediates tonic inhibition, especially through inhibition of
glutamate release from presynaptic nerve endings (27). The
A2AR is concentrated in dopamine-rich regions (18), especially
on striato-pallidal GABAergic neurons (23), where it exerts
excitatory effects on neurons and contributes to inhibition of
motor activity (29). The A2AR actions are complicated by the
fact that it co-localize and form heteromeres with dopamine-,
cannabinoid-, and glutamate receptors (23). The roles of A2BR
and A3R are not as well understood, but it appears that adenosine
has a lower affinity for these receptors compared to A1R and
A2AR receptors. Their activation is more likely to happen under
conditions of hypoxia during which there is increased adenosine
availability (30, 31).
The Caffeine’s Effects Are in General
Opposite to the Effects of Adenosine
The brain levels of adenosine in cats and rodents in resting
physiological condition have been estimated to 30–200 nM/L,
concentrations sufficient to activate A1, A2A and possibly A3
receptors if numerous on the cells (30, 31), but in most tissues
the adenosine signaling is not very prominent (14). Even low
concentrations of caffeine, such as 1–10µM achieved after
consumption of a single cup of coffee, result in significant
antagonism of adenosine A1 and A2A receptors and may result
in increased alertness (32).
Sleep and Arousal
An important function of adenosine in the CNS is its involvement
in the sleep/arousal system. Adenosine has sleep-promoting
effects (33). During sustained and prolonged wakefulness the
extracellular adenosine accumulates in the basal forebrain
cholinergic region, and it declines slowly during recovery sleep
(34). This rise of adenosine reduces the cortical activity by
direct A1R modulation of the corticopetal system, the major
extrathalamic relay of the reticular ascending system (RAS) to the
cortex, and indirectly via A2AR-modulation of the hypothalamus
(35). It has been shown, for instance, that infusion of a
specific A2AR agonist into the subarachnoidal space, inducing
NREM sleep, will cause increased activity in the ventrolateral-
preoptic (VLPO) area of the anterior hypothalamus and a
reduced activity of the tuberomammilary nuclei (TMN) in the
posterior hypothalamus as seen by increased number of Fos-
positive neurons (36). Caffeine-induced wakefulness depends on
adenosine A2A receptors (37). It seems that blocking of A2AR in
nucleus accumbens inhibits the GABAergic output to the lateral
hypothalamus, the TMN and the locus coeruleus (LC), causing
activation and the major arousal effect of caffeine (38). Genetic
knockout models have shown that both A1 and A2A receptors
are involved in mediating the sleep-promoting properties of
adenosine in the brain (39). Moreover, the arousal effects of
caffeine seen in wild-type animals are blunted in ADORA2A-
knockout mice (38). It is therefore conceivable that adenosine
receptor ligands could be used as normal cognitive enhancers or
sleep promoters.
Pain
Experimental data indicate that caffeine at doses between 25
and 100 mg/kg have intrinsic antinociceptive effects (40). To
extrapolate data derived from animal experiments to humans,
it is generally assumed that giving 10 mg/kg caffeine to a rat
corresponds to giving 3.5 mg/kg (about two to three cups of
coffee) to a 70 kg human (18), although such an assumption
may be premature given the higher metabolic rate of rodents
and hence the shorter half-life of caffeine in their system. Based
on this assumption, caffeine at doses around 600–1,200mg
may be needed to achieve anti-nociception in caffeine-naive
humans. As an adjuvant caffeine (≥65mg) can potentiate the
analgesic properties of other medications (4, 41) by 40% (42),
and there is a possibility that caffeine alone in such low doses
might have intrinsic analgesic properties for some types of
pain, such as headache. Ward et al. employed a double-blind
placebo-controlled crossover design to assess whether caffeine
alone (60 and 130mg) has independent analgesic effects on
non-migrainous headaches, and found equivalent effects to
acetaminophen (43). Caffeine, and combination analgesics with
caffeine may be used in tension-type headache, but frequent use
is not recommended due to the risk of developing medication-
overuse headache (41). It is also used in hypnic headache (44)
and post-lumbar puncture headache (45), but probably not to the
analgesic effect per se. In hypnic headache the effect of caffeine
is claimed to go “beyond the usual analgesic effects observed
in other headache disorders” (44). Hypothalamic effects, as
described in the next section, may play a role. The effect
on post-lumbar puncture headache, which has “not conclusive
evidence” according to a Cochrane report from 2013 (45), has
been attributed non-analgesic mechanisms, including adenosine-
mediated vasoconstriction (46, 47).
Analgesic properties of caffeine may be hard to reconcile
with analgesic effects of adenosine. When the concentrations of
adenosine increase during stressful conditions, including noxious
stimulation, it may reduce pain (48), and adenosine receptor
agonists produce antinociception in a variety of pain models
(49). Mice lacking A1R show signs of increased anxiety and
hyperalgesia, and the antinociceptive effects of adenosine seen
in wild-type mice (50) cannot be shown (48). A1R is present
on peripheral sensory nerve terminals and in lamina II of the
spinal cord, and it has been suggested that peripheral anti-
nociception achieved by activation of A1R occurs via blocked
release of endogenous calciton gene-related peptide (CGRP)
(51) and substance P (52). Under inflammatory conditions,
experimental data indicate that the analgesic effect is by
reducing hypersensitivity through a central mechanism (49,
53). This is in accordance with human studies, showing that
intrathecal injection of adenosine does not cause antinociception
to acute thermal or chemical stimuli, but reduce allodynia
from intradermal capsaicin injection (53). Adenosine may also
increase pain mediated by A2A receptors (28). Experimental data
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indicate that there are pro-nociceptive A2ARs on the peripheral
nerve terminals (28, 54), and that blocking of these may cause
antinociception (40). Caffeine in doses normally consumed by
humans can probably act as an analgesic, partly through blockade
of A2A receptor (40). Central dopaminergic mechanisms may
also be involved. Like other analgesics (55), caffeine increases
dopamine release (18), probably via inhibition of A2AR (56).
Notably, A2A receptor antagonists did not affect dural meningeal
vasodilatation caused by CGRP in a rat model (57). The recent
marketing of CGRP receptor antibodies and the development of
CGRP antagonists has been considered a major breakthrough
in the migraine field (58). Despite the fact that A2AR does not
appear to be located in the spinal cord, a specific inhibition of
the activity of the intermediolateral cell column (the sympathetic
system) was shown by Brooks et al., indicating that the A2AR
may be located on presynaptic inhibitory terminals of descending
fibers from higher brain centers (59).
It is clear that both adenosine and blockade of adenosine
by caffeine may cause anti-nociception. Since the nanomolar
affinities of adenosine for A1R and A2AR are almost the same,
this indicates a fine balanced modulation of the pain processing
(30), making it very difficult to predict the net effects of caffeine
on nociception in humans.
Caffeine Overuse and Withdrawal
Caffeine causes increased well-being in small to moderate doses
and its overuse has the potential to cause physical dependence
(60). The caffeine dependence syndrome has been recognized by
the World Health Organization as a behavioral disorders due
to frequent use of caffeine (61). Considerable evidence suggests
that this is due to enhanced dopaminergic activity, especially
via blocking of A2AR causing increased dopamine release in
the ventral striatum (nucleus accumbens) (26). However, there
is a compensatory up-regulation of the adenosine system,
causing increased functional sensitivity to adenosine during
withdrawal (5, 10). These molecular changes appear to increase
functional sensitivity to adenosine during caffeine abstinence,
and play an important role in the behavioral and physiological
effects produced by caffeine withdrawal (5, 10). In humans,
caffeine withdrawal following chronic consumption may give
rise to a time-limited syndrome comprising of headache,
drowsiness, mood-changes, difficulty focusing, nausea, and
muscle pain/stiffness (Box 1) (5, 6, 62). Consequently, caffeine
consumption may be maintained to avoid withdrawal symptoms.
Caffeine-withdrawal headache is a headache developing within
24 h after regular consumption of caffeine in excess of 200
mg/day for more than 2 weeks, which has been interrupted.
According to the ICHD3 classification, this type of headache
resolves spontaneously within 7 days in the absence of further
consumption (10).
Further, repeated exposure to caffeine may lead to rapid
development of tolerance, preferentially to the A1-blocking
effect, and in some cases it evenmay result in opposite effects than
expected (14). By drinking three to four cups of coffee regularly
around 50% A1 and A2A receptor occupancy can be achieved for
several hours, and many of the actions of caffeine are due to this
AR blockade (18).
TABLE 1 | Caffeine withdrawal symptoms and migraine prodromal symptoms.
Frequent symptoms
reported in different
studies (underlined are
the major criteria in the
withdrawal syndrome)
Juliano
(7)
Quintela
(64)
Schoonman
(65)
Caffeine
withdrawal
symptom,
% (*)
Migraine
prodromal
symptom, %
(n = 100)
Migraine
prodromal
symptom, %
(n = 461)
Tiredness/fatigue/asthenia 21–56 31–38 47
Drowsiness/sleepiness 18–59 35
(“somnolence”)
NA
Difficulty concentrating 27–50 36 28
Mood change
Depression/sadness 16* 39 18
Irritability 21 42 28
Yawning 21–43** 40 36
Nausea 3–33*** 24 29
Sensory hypersensitivity
Phonophobia NR 37 36
Photophobia 14 (blurred
vision****)
44 *****
Anxiety 10–29 46 NA
Craving 28–43****** 15 17
Thirst NR 17 NR
Muscle pain/stiffness 43 NA 35 (stiff neck)
*Data were collected from 57 experimental and nine survey studies. **21% reported in one
survey and 43% in one experimental study. According to Juliano et al. (7) further research
is needed to determine the validity of yawning as a withdrawal symptom. ***3–21% in
surveys and 10–33% in experimental studies. ****Blurred vision was demonstrated in only
2 of 11 experimental studies. *****Photophobia was excluded in this study. ******Reported
in 2 of 2 experiments. According to Juliano et al. (7) further research is needed to determine
the validity of craving as a withdrawal symptom. NA, not assessed, NR, Not reported.
The Migraine Syndrome
Migraine is a disorder characterized by recurrent attacks of
head pain associated with hypersensitivity to sensory stimuli
(10) and when full-blown it involves different phases (63). (a)
A prodromal or premonitory phase hours prior to the onset of
the headache with a broad range of symptoms (Table 1), which
patients can reliably recognize, and thus predict the occurrence
of a headache, (b) Transient neurological symptoms, known
as migraine aura (typically visual alterations), just before the
actual headache starts (in migraine with aura patients), (c)
An intense headache, typically involving only one site of the
head, accompanied by nausea, sensitivity to light, noise and
smells, (d) The postdrome phase following the resolution of the
headache and characterized mainly by fatigue and inability to
concentrate (66). Understanding the mechanisms involved in
the transition from a headache-free to the headache state is
crucial in understanding the underlying cause of headaches and
the development abortive drugs. In many primary headache
disorders, but especially migraine (67, 68), several external
factors have been reported to trigger this transition; stress,
bright light and lack of sleep are probably the most commonly
reported (69). The periodicity of migraine attacks strongly
indicates involvement of internal clock mechanisms in its
pathophysiology (70).
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Does the Migraine Prodromal Syndrome and
Caffeine-Withdrawal Syndrome Share the Same
Symptoms?
The prodromal, or premonitory, phase of migraine is usually
defined as the period 2–48 h prior to aura or migraine headache
with symptoms (Table 1) indicating an attack. Thirty to 90%
of migraine patients report such a phase (71). In a prospective
electronic diary study, Giffin et al. found that yawning, increased
emotionality and concentration difficulties (difficulty reading and
speaking) were the most reliable predictors (72). In another
study by Schoonman et al., where patients had to choose
among 12 specific premonitory symptoms, the most frequently
reported were fatigue, phonophobia and yawning. Increased
emotionality and concentration difficulties were reported by
almost one third (10). Kelman found that tiredness, mood
change and gastrointestinal symptoms (nausea) were the most
frequent reported symptoms, and that yawning was rarely
reported (69). However, there were specific questions about the
former categories, but none about the latter symptom. In a
prospective survey of 100 unselected patients, Quintela et al. (64)
found that anxiety, phonophobia, irritability, unhappiness and
yawning were the most common reported prodromal symptoms,
whereas asthenia, tiredness, somnolence and concentration
difficulties were the most common symptoms reported in the
postdromal phase. Due to different methodologies used to
identify symptoms, it may be difficult to compare results from
different studies, but interestingly, the most prevalent symptoms
reported are much the same as the symptoms of the caffeine-
withdrawal syndrome. In Table 1 findings from the very good
and comprehensive review about caffeine withdrawal symptoms
made by Juliano et al. (7) are compared with findings from two
of the mentioned surveys. These data strongly suggest that the
same or similar pathophysiological pathways may be involved
in both the prodromal phase of migraine and the caffeine
withdrawal syndrome. However, sensory hypersensitivity, a
cardinal migraineous feature (10), does not seem to be part of
the caffeine withdrawal syndrome. This may nevertheless be due
to an underlying thalamocortical dysrhythmia (73), that appears
to be specific for migraine. The overlap of symptoms may also be
due to the fact that caffeine withdrawal may act as a trigger of a
migraine attack in migraine patients?
Is the Caffeine Withdrawal Headache Similar to
Migraine?
Headache as a caffeine withdrawal symptom has been frequently
studied (7), and in some case reports and experimental
studies it has been characterized. However, premorbid primary
headache syndromes, even in otherwise solid papers (74), are
seldom reported. It seems though that subjects with a history
of frequent headaches (75) are at increased risk, and that
migraineurs and subjects who experience withdrawal headache
share some comorbidity such as major depression and anxiety
(5). To “produce experimental headaches which would be
more physiological than experimental histamine and nitrite
headaches,” Dreisbach in 1940 gave a number of non-habitual
coffee drinkers capsules of 10–12 grains (650–780mg) of caffeine
daily for 1 week and then withdrew the treatment. On the
day of withdrawal, almost all developed a moderate to severe
headache. In migraineurs, “typical migraine syndromes” ensued
(8). Unfortunately, the report does not give sufficient data
for valid interpretation. Three years later, however, he and a
colleague reported 38 similar trials in 24 persons of whom 5 had
migraine. In 21 of the trials the subjects experienced their worst
headache ever, in 11 it was definite but not severe, and in 6 there
was slight or no headache. All of the migraineours experienced
caffeine withdrawal headache “quite different from the migraine
syndrome.” It is reason to question this statement. The headache
was accompanied by nausea in 4 and vomiting in 1. In 4
subjects the headache was consistently accompanied by serous
rhinorrhea. This may indicate cranial autonomic symptoms,
frequently seen in migraine (76). No information about other
accompanying symptoms was given. It was argued that 2 subjects
had headache localized to the opposite side of the head from
their usual migraine. In one subject, who used to have left-sided
frontal migraine, it occurred bilaterally and was localized in the
occipital region. Our clinical experience, however, confirms that
is not unlikely for migraine to switch sides or to be bilateral rather
than unilateral. Scotomas, regularly experienced by 3 migraine
patients, did not occur. Scotoma, is a symptom usually described
in migraine with aura patients and to date no headache-induced
substance has been found to consistently trigger migraine aura.
Further, two of the migraineurs had migraine attacks on the
height of the caffeine stimulation, and in one of these subjects this
reoccurred in a second trial. In these trials, and in later studies the
headache is described to typically evolve gradually (60, 77, 78),
being diffuse (79), throbbing (9), severe (60, 80), intensified with
exercise (77), and Valsalva manoeuver (9) and having a mean
duration for 2–3 days (81).
Despite being claimed that caffeine-related headache has a
non-migrainous clinical presentation (82), the description of
caffeine withdrawal headache given in the literature is not
very different from migraine. With the high prevalence of
migraine (83), and the lack of information on pre-existing
headache in many studies taken into consideration, there seems
to be a clear shortcoming in the knowledge when it comes to
separating caffeine withdrawal as a migraine trigger from caffeine
withdrawal headache per se.
Does Caffeine Cause Headaches?
Caffeine itself is rarely reported as a trigger of migraine (68),
but as noticed by Driesbach it probably has the potential (9). As
an important cause of medication-overuse headache (84) caffeine
has been strongly incriminated, partly due to the withdrawal
syndrome encouraging patients to continue their overuse (85–
87). In a double blinded, randomized, placebo-controlled, 12
week crossover study of 45 healthy subjects who habitually
consumed 4 to 6 cups of coffee a day (81),withdrawal caused
headaches during the first or second day in 19 (42%) (81). The
ratio of subjects reporting headaches during caffeine weeks and
during non-caffeine weeks was 1. However, what is obvious, but
not commented by the authors, is that when the withdrawal
weeks (week 1 and 7) are removed the ratio increases to
7.7. Subjects also reported improved sleep during the non-
caffeine weeks.
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Caffeine-overuse may even cause chronic headache in
children (15). Hering-Hanit and Gadoth reported 36 children
with chronic headache, none with a prior history of migraine,
who consumed excessive amounts of caffeine in the form of
cola drinks (in average ∼190mg caffeine/d), and of whom 33
completely recovered after gradual withdrawal. Three children
continued to have infrequent migraine without aura after
withdrawal (15). In general, most chronic daily headaches in
children appear to be migraine related (88). Caffeine has also
been a suspected risk factor for episodic migraine evolving
into chronic migraine, which in essence is defined as headache
on ≥15 d/month for >3 months (66). A strong positive
correlation between caffeine consumption and both episodic (89)
and chronic migraine (90) has been found. In a retrospective
population-based study, Scher et al. found that dietary and
medicinal caffeine consumption appears to be only a modest
risk factor for developing chronic daily headache, including
chronic migraine (91). Overall, no relationship between current
caffeine consumption and headache was found, neither was that
found in two further studies (92, 93). However, in the cross-
sectional population-based study by Boardman et al., headache
sufferers were more than twice as likely to be heavy caffeine
consumers compared to non-sufferers (92). In a Norwegian
large-scale cross-sectional population-based study only a small
association between high consumption of caffeine (>540 mg/d)
and infrequent migraine was found (94). In this study chronic
headache was more prevalent among individuals with low
caffeine consumption (mean of 125 mg/d).
In general, chronic consumption of caffeine seems to be
associated with increased migraine burden. Either chronic
caffeine increases the risk of migraine per se, or in contrast,
has beneficial effects in patients severely affected by migraine.
Whether long-term elimination of caffeine diet will reduce the
migraine burden has not been studied previously.
Pathophysiological Aspects
In 1990, Welch et al. substantiated the concept of migraine
as a state of central neuronal hyperexcitability (95). Later it
has become clear that some sort of cortical dysexcitability
may even be present between attack (73). The mechanisms
underlying the abnormal regulation of cortical function and the
cyclic features of migraine remain largely unknown, but older,
largely intuition based theories of hypothalamic dysfunction
as the cause of periodicity of attacks have in recent years
had a renaissance, especially after brain imaging evidence of
hypothalamic activity both in the prodromal (96) and the pain
phase (97) of migraine. There is accumulating indirect evidence
for a pivotal role of hypothalamus in many primary headache
disorders (98–102). The discovery of a mutation in a clock-
gene (CK1δ) causing so called familiar advanced sleep phase
syndrome was strongly linked to migraine both clinically and
experimentally (103). Mice engineered to carry the mutation
exhibit lower threshold for cortical spreading depression (CSD),
the phenomenon underlying aura (see beneath), and increased
sensitivity to noxious stimuli after nitro-glycerine treatment.
A clear relationship between sleep and migraine exists (104),
and caffeine can certainly disrupt sleep (105). Disrupted sleep-
patterns predispose, and sleep per se protects against migraine
(100). The risk of getting a migraine attack is low during
sleep, but spikes in the morning, especially when associated
with insomnia (106), and peaks in the afternoon probably due
to work-related stress (107). Menstrual migraine and weekend
headaches are also clear examples of the periodicity. The higher
prevalence of migraine on weekend mornings reported was
attributed to caffeine withdrawal by Couturier et al. (108).
Adenosine Can Cause Headache
It is now accepted that the pain during a migraine attack is
perceived to be felt on intracranial structures, such as, the
dura mater and intracranial vasculature (109, 110). Activation
of the ophthalmic division (V1) of the trigeminal nerve is
regarded primarily responsible for causing the pain in primary
headache disorders (102). Upon activation of the trigeminal
fibers, several neuropeptides such as substance P, neurokinin
A, calcitonin gene-related peptide (CGRP), pituitary adenylate
cyclase activating peptide (PACAP) and nitric oxide (NO) are
released into the innervated tissue (dura mater and meningeal
vessels) with the potential to cause neurogenic inflammation.
Migraine has been attributed to such a local sterile meningeal
inflammation (111), possibly involving release of histamine
from mast cells (112). Activation of the trigeminal fibers is
referred to as “trigeminovascular activation” and is considered
the key event in causing headache. Accumulating data support
a pivotal role of CGRP in migraine (58), and when given
intravenously a delayed migraine-like headache will be induced
in a large fraction of migraineurs but not in controls (113).
CGRP causes only a modest, around 10%, vasodilation which
is unlikely to activate perivascular trigeminal afferents (114).
In general, the former “vascular theory” of migraine has been
abandoned by several experiments showing that vasodilatation
of neither extracranial- or intracranial/meningeal arteries is
neither necessary nor sufficient to cause migraine headache
(113). However, vasodilatation may worsen pain in an already
sensitized pain network. The trigeminal fibers, that carry the
sensory information from the intracranial structures, project
on second-order neurons within the trigeminocervical complex
(TCC; trigeminal nucleus caudalis, C1 and C2 spinal levels).
These neurons give rise to the main ascending trigeminothalamic
pathway that carries sensory information to third order neurons
in the thalamus, before processing the information to higher
cortical areas (115).
As with other recognized experimental triggers of migraine
(116), such as CGRP, it is hard to conceive how adenosine
itself, not passing the blood-brain barrier readily (14), could
act centrally to elicit a migraine cascade. Further, adenosine
has been ascribed peripheral anti-nociceptive effects by blocking
the release of CGRP (51). Nevertheless, increased levels of
adenosine in the blood during migraine attacks have been
reported (117), and headaches are often reported when adenosine
is used intravenously in cardiology (118). The A2A agonist
regadenoson does also induce headache frequently (119). The
drug dipyramidole, which increases the level of adenosine by
inhibiting adenosine re-uptake, can cause headache as an adverse
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effect in one third of the patients. It has been also reported to
increase the migraine frequency in migraine patients (120) and
to elicit migraine in an experimental setting (121). In addition,
intravenous application of adenosine can trigger migraine attacks
(122). Based on this, antagonizing adenosine by caffeine may
theoretically have an abortive effect in migraine. The problem
is, as mentioned earlier, that chronic caffeine consumption in
humans seems to increase the migraine burden. Supported by
experimental findings (123, 124), an increased vascular tone
due to up-regulation of adenosine receptors and compensatory
increased levels of plasma adenosine have been suggested
mechanisms underlying this risk (125, 126). Increased cerebral
blood velocities have been measured after caffeine withdrawal
(12), and there is no doubt that caffeine has the opposite
effect causing a decrease in cerebral blood flow due to central
vasoconstriction. However, the neuronal-vascular coupling is
complex and in a functional magnetic resonance imaging study
(fMRI), reduced cerebral perfusion induced by caffeine was
independent of previous caffeine consumption (127). In a study
of the rat middle meningeal artery, caffeine was found to reverse
the relaxing effect of adenosine, mainly mediated by blocking of
A2AR (128). Whether vasoconstriction significantly contributes
to the effects of caffeine in withdrawal headache remains unclear
since vasodilation hardly is a primary cause of the headache.
As mentioned earlier, blocking of A2AR does not seem to
affect neurogenic vasodilation (57). Further, discrepancy between
different studies has been observed. In an experimental cat
migraine model, the A1R agonist GR79236 had a dose-dependent
inhibitory effect on trigeminovascular nociceptive transmission
(129). This effect was explored in humans. In 12 healthy female
volunteers the adenosine A1 receptor agonist GR79236 was
shown to inhibit trigeminal nociception, as measured by the
blink reflex (130). Further studies in pigs did not show any effect
on capsaicin-induced CGRP release (131), and in a multicenter
evaluation of the adenosine agonist GR79236X in patients with
dental pain after third molar extraction, no efficacy was shown
when compared to placebo (132).
Caffeine Has the Ability to Induce Cortical
Excitability, and May Even Predispose for CSD?
Traditionally, the migraine aura has been considered a distinctive
phase, but probably it is a consequence of the same or parallel
mechanisms that triggers the pain (133, 134). It is believed
that the migraine aura itself is caused by so called cortical
spreading depression (CSD) (135). CSD is a wave of neuronal
depolarisation linked with depressed neuronal activity and blood
flow changes (136). In animals, CSD can quite readily be induced
by focal cortical stimulation for example by applying K+ (137).
Despite being accepted by most experts as a plausible mechanism
of migraine aura and even headache in migraine without aura
(“silent spreading depression”) it has been difficult to prove that
CSD actually is the underlying mechanism in humans. It also
remains enigmatic howCSD could be triggered in patients during
migraine. So called calcium waves in astrocyte networks is a
speculative (138), but alluring mechanism that could offer an
alternative explanation to the classical CSD. Recent advances
support the idea that astrocytes could play an important role
in spreading depression initiation (139). ATP-receptors (P2
receptors) are both necessary and sufficient for propagation of
calcium waves (140), and thus has the potential to initiate and
sustain a heighten state of neuronal excitability. Caffeine may
possibly modulate this susceptibility (141). An A2A receptor gene
haplotype has been reported to be associated with migraine with
aura (142), but the findings should be reproduced. There appears
to be only one published case where intravenous adenosine
precipitated migraine aura (122). Activation of A1R has been
shown to increase K+ conductance and thus hyperpolarize CNS
neurons (50). It is thus more plausible that acute caffeine could
increase the susceptibility to CSD, and pre-published reports
supported that (143, 144). However, caffeine exposure did not
affect the susceptibility to CSD in a recent study of mice (82).
Curiously, CSD can induce yawning in rats (145).
Yawning Indicates Hypothalamic Alterations
It has been demonstrated that activating the A1R on TMN-
neurons increases NREM sleep (146), and that blocking them
on hypocretinergic neurons of the lateral hypothalamus increases
wakefulness (147). Both neurotransmitter systems have been
suggested to play an important role in migraine (148, 149).
The TMN of the posterior hypothalamus has been suggested to
play a role in the initial phases of a migraine attack and to be
responsible for the morning occurring migraine attacks (148,
150). During drowsiness and normal recovery sleep the firing
from the histaminergic neurons are reduced or absent, but during
wakening and arousal they fire, allegedly the most wake-selective
firing pattern identified to date (151). Adenosine may well have
a protective effect against migraine during sleep, but during
non-recovery sleep and wakefulness disrupted homeostasis may
cause increased histaminergic firing predisposing for headaches.
It has been postulated that yawning is the manifestation of a
switch in brain states from “default mode” to an “attentional
mode” by increasing clearance of adenosine (152). It remains to
be proven in experimental models that increased histaminergic
firing sensitizes the TCC.
Yawning may also be indicative of an individual’s inability
to properly maintain thermal brain homeostasis (153). If
yawning occurs without being associated with tiredness, it
may perhaps indicate a thermoregulatory dysfunction. In the
study of Schoonman et al. of the premonitory symptoms of
migraine there was no correlation between “sleep problems” and
yawning (Spearman’s rank correlation of 0.024) (65). Further,
Jacome described 3 migraineurs with compulsive yawning as
a prodromal symptom, independent of fatigue and drowsiness
(154). In a recent cross-sectional study, 45.4% of 339 migraineurs
reported repetitive yawning during migraine attacks (155).
Sleepiness was significantly more often reported in patients with
yawning compared to those who did not yawn during their
migraine attacks.
Thermoregulation and sleep are interrelated. It is well-known
that yawning has a clear circadian pattern parallel to the rise
in body and brain temperature, normally occurring most often
before sleep onset and after waking (153). A hypothesis that
migraine attacks serve to restore the brain temperature has
recently been put forward (156). In general, the neurons of
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the brain are very sensitive to variations in the temperature
(157). Short visual stimulation of the rat invokes a rise in
temperature over the visual cortex (158), and during prolonged
(4min) visual stimulation inman, an increase in regional cerebral
blood flow caused an average decrease in temperature by 0.2◦C
(159). Histamine has been shown to mainly excite heat-sensitive
neurons in the anterior hypothalamus, causing hypothermia. In
contrast to adenosine (160), caffeine increase body temperature
parallel to arousal during circadian misalignment in humans
(161). Injecting neuropeptide orexin-A into the rat PVN elicits
a cortical arousal response followed by yawning (162), and
injecting it into the ventromedial hypothalamus it induces
hyperthermic reactions (163).
Based on the fact that migraineurs show a lower threshold for
central dopamine receptor activation than normal subjects (164),
and that exogenously administered dopamine receptor agonists
may produce some symptoms experienced in the prodromal
phase of migraine such as drowsiness and yawning, dopamine
may play an important role in migraine pathophysiology. This
theory is consistent with the idea that caffeine withdrawal
symptoms are due to increased sensitivity of adenosine,
causing increased drowsiness (due to increased disinhibition
of VLPO sleep-active neurons reducing histaminergic tone)
and excessive yawning due to increased dopaminergic tone. It
has been shown that injecting dopamine (D2) agonists into
the paraventricular nucleus of the hypothalamus (PVN) of
rats, increases local nitric oxide (NO) production and thereby
activates central oxytocinergic neurotransmission, inducing
yawning (165). However, microinjection of other substances
into the PVN, such as histamine (166) and nitroglycerine (167)
also induces yawning. As distinct from dopamine agonists,
that seldom induces headache (168), both donors of NO and
histamine are established triggers in pharmacological models of
migraine (116). Glyceryl trinitrate has even been shown to both
induce prodromal symptoms of migraine (169) and activate the
hypothalamus (96).
Caffeine Can Alter the Circadian System and
Neuronal Excitability
It has been proposed that the hypersensitivity to light during
migraine may be exerted by intrinsically photosensitive retinal
ganglion cells (ipRGCs) through a pathway that modulates
the activity of dura-sensitive thalamocortical neurons (170).
The ipRGCs entrain the circadian rhythms and influence
sleep/wakefulness (171). Adenosine, through A1R inhibition
of glutamate release, seems to fine-tune the circadian system
through gating of both photic and non-photic input to the
superior biological clock, the suprachiasmatic nucleus (27).
Giving an A1R agonist during midday, phase-shift mimicking
the effect of a 3 h sleep deprivation procedure may be achieved
in hamsters (172). Caffeine increases light responsiveness of the
mouse circadian pacemaker (173), and it has been shown that
chronic exposure to caffeine interferes with the ability of the
SCN to entrain normally to light, and that it potentiates phase-
delays (174). Further, it has been claimed that glasses that filter
out blue light can reduce the frequency of migraine attacks
with short periods of usage (175), and in an experimental study
light stimulation with the peak wavelength of ipRGC induced
migraine attacks more frequently than extensive-wavelength
(176). Based on this, it may be speculated that caffeine interferes
with the ability of the biological clock to entrain to light, causing
increased excitability in pathways involved inmigraine headache,
including the dura-sensitive thalamocortical neurons.
The pharmacology of both the TCC and the thalamus provides
interesting insights into migraine pathophysiology, as they are
prominent sites of action of migraine specific medication-
triptans (177), of clinically active preventives (178, 179) and of
other potential anti-migraine compounds (180). The modulation
of sensory transmission in the thalamus, assumes further
significance as it has been shown not only to be a pivotal area
for the development of sensory hypersensitivity to light during
migraine (170), but could also participate in the development
of hypersensitivity to noise (181), and non-cranial allodynia
that is frequently seen in migraine patients (182). Experimental
data show that presynaptic adenosine A1 receptors on thalamo-
cortical neurons canmediate reduced cortical excitability directly
(183). When interacting with serotonin, adenosine may also
modulate thalamic sensory gating during sleep (184). If the
caffeine withdrawal syndrome is due to increased sensitivity
to adenosine, this may explain why sensory hypersensitivity
is not a symptom of caffeine withdrawal. It is tempting to
speculate that caffeine can increase the sensory hypersensitivity
that accompanies migraine headache.
Both the TCC and the thalamus have reciprocal direct or
indirect connections with multiple brainstem, midbrain and
cortical nuclei that control the excitability of the ascending
trigeminothalamic pathway (185). These brain nuclei make
up the descending pain modulatory system (115), which
is a powerful regulator of pain-related activity along the
ascending trigeminothalamic pathway. Disruption of normal
endogenous descending modulatory tone may play a critical
role in primary headache disorders, but what really alters
the excitability of the ascending trigeminothalamic pathway
in a manner that a migraine attack develops in susceptible
individuals, remains to be revealed. As mentioned earlier, central
dopaminergic mechanisms (via A2AR) may be involved. In an
experimental headache model, stimulation of the dopaminergic
A11 significantly inhibited peri-MMA dural and noxious pinch
evoked firing of neurons in the TCC, an effect that was blocked
by a D2 receptor antagonist (186). Whether the A11 neurons
have adenosine receptors, and whether caffeine induces release
of dopamine from the A11 nucleus, is not known.
CONCLUSION
The current opinion is that caffeine both can relieve and
trigger headaches. It has to be clarified whether caffeine
withdrawal triggers or merely resembles the migraine syndrome.
The nature of the caffeine withdrawal syndrome needs to be
better understood. In assessing the clinical effects of caffeine
withdrawal, there is a chance that a triggered migraine syndrome
is interpreted as part of the caffeine withdrawal syndrome,
explaining an overlap between these two. If it triggers migraine it
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offers a good human migraine model. A clinical trial thoroughly
evaluating the withdrawal syndrome specifically in subjects with
migraine should be performed. Furthermore, whether long-term
elimination of caffeine diet will reduce or increase the burden of
migraine should also be evaluated.
There is compelling evidence that adenosine may trigger
headaches, but how this poor blood-brain-barrier penetrating
substance can trigger central mechanisms when given
intravenously remains enigmatic. Chronically blocking
adenosine receptors by habitually drinking coffee seems
to increase the burden of migraine, and it is tempting to
believe that this causes an increased sensitivity to adenosine,
evident when caffeine is withdrawn. Caffeine withdrawal
and migraine prodromal symptoms are definitely caused
by alterations in the CNS. Looking beyond the peripheral
effects, central adenosine mechanisms should be explored in
experimental headache models. The link between adenosine,
the circadian system, sleep, and pain points at the posterior
hypothalamus as a locus in quo. The effects of caffeine on
the TMN and the A11 may offer novel insight, and the A2AR
seems to be of particular interest. Two positron emission
tomography (PET) A2AR-ligands have been developed, and
this may render human in vivo imaging studies possible
(14). Future research should also confirm and investigate
a role of receptor genes like ADORA2A in migraine and
caffeine withdrawal.
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